These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
803 related articles for article (PubMed ID: 33958057)
1. The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. Klassen SA; Senefeld JW; Johnson PW; Carter RE; Wiggins CC; Shoham S; Grossman BJ; Henderson JP; Musser J; Salazar E; Hartman WR; Bouvier NM; Liu STH; Pirofski LA; Baker SE; van Helmond N; Wright RS; Fairweather D; Bruno KA; Wang Z; Paneth NS; Casadevall A; Joyner MJ Mayo Clin Proc; 2021 May; 96(5):1262-1275. PubMed ID: 33958057 [TBL] [Abstract][Full Text] [Related]
2. The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality: Systematic Review and Meta-analysis. Klassen SA; Senefeld J; Johnson PW; Carter RE; Wiggins CC; Shoham S; Grossman BJ; Henderson JP; Musser JM; Salazar E; Hartman WR; Bouvier NM; Liu STH; Pirofski LA; Baker SE; Van Helmond N; Wright RS; Fairweather D; Bruno KA; Paneth NS; Casadevall A; Joyner MJ medRxiv; 2021 Feb; ():. PubMed ID: 33140056 [TBL] [Abstract][Full Text] [Related]
3. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. Senefeld JW; Franchini M; Mengoli C; Cruciani M; Zani M; Gorman EK; Focosi D; Casadevall A; Joyner MJ JAMA Netw Open; 2023 Jan; 6(1):e2250647. PubMed ID: 36633846 [TBL] [Abstract][Full Text] [Related]
4. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927 [TBL] [Abstract][Full Text] [Related]
5. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Piechotta V; Iannizzi C; Chai KL; Valk SJ; Kimber C; Dorando E; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2021 May; 5(5):CD013600. PubMed ID: 34013969 [TBL] [Abstract][Full Text] [Related]
6. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial. Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ Trials; 2021 May; 22(1):342. PubMed ID: 34001174 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of convalescent plasma therapy for COVID-19: A systematic review and meta-analysis. Vegivinti CTR; Pederson JM; Saravu K; Gupta N; Evanson KW; Kamrowski S; Schmidt M; Barrett A; Trent H; Dibas M; Reierson NL; Mikoff N; Pisipati S; Joseph BA; Selvan PT; Dmytriw AA; Pulakurthi YS; Keesari PR; Sriram V; Chittajallu S; Brinjikji W; Katamreddy RR; Chibbar R; Davis AR; Malpe M; Mishra HK; Kallmes KM; Hassan AE J Clin Apher; 2021 Jun; 36(3):470-482. PubMed ID: 33544910 [TBL] [Abstract][Full Text] [Related]
9. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T; Trials; 2021 May; 22(1):343. PubMed ID: 34001215 [TBL] [Abstract][Full Text] [Related]
10. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. Joyner MJ; Carter RE; Senefeld JW; Klassen SA; Mills JR; Johnson PW; Theel ES; Wiggins CC; Bruno KA; Klompas AM; Lesser ER; Kunze KL; Sexton MA; Diaz Soto JC; Baker SE; Shepherd JRA; van Helmond N; Verdun NC; Marks P; van Buskirk CM; Winters JL; Stubbs JR; Rea RF; Hodge DO; Herasevich V; Whelan ER; Clayburn AJ; Larson KF; Ripoll JG; Andersen KJ; Buras MR; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Paneth NS; Fairweather D; Wright RS; Casadevall A N Engl J Med; 2021 Mar; 384(11):1015-1027. PubMed ID: 33523609 [TBL] [Abstract][Full Text] [Related]
11. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959 [TBL] [Abstract][Full Text] [Related]
12. Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials. Filippatos C; Ntanasis-Stathopoulos I; Sekeri K; Ntanasis-Stathopoulos A; Gavriatopoulou M; Psaltopoulou T; Dounias G; Sergentanis TN; Terpos E Viruses; 2023 Mar; 15(3):. PubMed ID: 36992474 [No Abstract] [Full Text] [Related]
13. Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG. Salazar E; Christensen PA; Graviss EA; Nguyen DT; Castillo B; Chen J; Lopez BV; Eagar TN; Yi X; Zhao P; Rogers J; Shehabeldin A; Joseph D; Masud F; Leveque C; Olsen RJ; Bernard DW; Gollihar J; Musser JM Am J Pathol; 2021 Jan; 191(1):90-107. PubMed ID: 33157066 [TBL] [Abstract][Full Text] [Related]
14. Convalescent plasma and all-cause mortality of COVID-19 patients: systematic review and meta-analysis. Mihalek N; Radovanović D; Barak O; Čolović P; Huber M; Erdoes G Sci Rep; 2023 Aug; 13(1):12904. PubMed ID: 37558729 [TBL] [Abstract][Full Text] [Related]
15. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308 [TBL] [Abstract][Full Text] [Related]
16. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747 [TBL] [Abstract][Full Text] [Related]
17. Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis. Jorda A; Kussmann M; Kolenchery N; Siller-Matula JM; Zeitlinger M; Jilma B; Gelbenegger G Front Immunol; 2022; 13():817829. PubMed ID: 35197981 [TBL] [Abstract][Full Text] [Related]
18. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. Balcells ME; Rojas L; Le Corre N; Martínez-Valdebenito C; Ceballos ME; Ferrés M; Chang M; Vizcaya C; Mondaca S; Huete Á; Castro R; Sarmiento M; Villarroel L; Pizarro A; Ross P; Santander J; Lara B; Ferrada M; Vargas-Salas S; Beltrán-Pavez C; Soto-Rifo R; Valiente-Echeverría F; Caglevic C; Mahave M; Selman C; Gazitúa R; Briones JL; Villarroel-Espindola F; Balmaceda C; Espinoza MA; Pereira J; Nervi B PLoS Med; 2021 Mar; 18(3):e1003415. PubMed ID: 33657114 [TBL] [Abstract][Full Text] [Related]